Exploring HPV and Genomic Changes in Head and Neck Cancer
Official title: Exploration of Human Papillomavirus Association and Genomic Characteristics in Head and Neck Squamous Cell Carcinomas in Bangladesh
Run by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · NCT06642324 · Data updated 2026-11-12
This study is trying to see how common HPV is in head and neck cancer patients in Bangladesh and what changes it causes in their cells.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 550 (estimated) |
| Sponsor | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Academic / other |
| Locations | 1 site (Dhaka, Dhaka Division) |
| Status | Recruiting |
| Started | April 30, 2024 |
| Main results expected | March 30, 2025 |
| Study ends | September 30, 2025 |
| Registry record updated | December 31, 2024 |
| Trial ID | NCT06642324 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old who have been diagnosed with head and neck squamous cell carcinoma.
✕Probably not a fit
Patients with cancers outside the head and neck region or those under 18 years old will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the prevalence and risk factors of head and neck squamous cell carcinoma (HNSCC) in Bangladesh, particularly focusing on the role of human papillomavirus (HPV) in its development. The study aims to identify the biological mechanisms and genomic changes associated with HPV-driven HNSCC by analyzing histopathology samples and conducting molecular screenings. By understanding these factors, the research seeks to provide insights into the public health challenges posed by HNSCC in the region.
Why it matters
Potential benefit: If successful, this study could lead to improved screening and prevention strategies for HPV-associated head and neck cancers in Bangladesh.
How similar studies have gone: Other studies have shown success in exploring HPV's role in head and neck cancers, indicating that this approach is supported by existing research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient Age: adult (\> 18 years) 2. Head and neck squamous cell carcinoma diagnosed by biopsy (Histopathology confirmed HNSCC). 3. Diagnosed cases specific Head-Neck sub-sites: (oral cavity, oropharynx, hypopharynx, larynx, tongue) 4. Patient's Consent Exclusion Criteria: 1. Patient Age: children (\< 18 years) 2. Cancers of any part of the body other than the head-neck region. 3. People without HNSCC 4. Any chronic diseases, genetic diseases, acute/chronic infectious diseases, etc. -
Where it's running
-
Bangabandhu Sheikh Mujib Medical University (BSMMU)
Dhaka, Dhaka Division, Bangladesh Recruiting
Study contacts
- Principal investigator: S M Rashed Ul Islam, M. Phil, MPH — Bangabandhu Sheikh Mujib Medical University (BSMMU)
- Study coordinator: S M Rashed Ul Islam, M. Phil, MPH
- Email: smrashed@bsmmu.edu.bd
- Phone: +8801713236399
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Proton Re-irradiation for Recurrent or Second Primary Head and Neck Cancer
This study tests proton radiotherapy to see if it can control head and neck cancer that has come back or appeared again in the same area, while trying to limit side effects.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
-
BupiZenge vs Lidocaine for mouth pain from oral mucositis in head and neck cancer
A phase 3 trial tests whether the BupiZenge lozenge provides better pain relief than lidocaine for mouth sores caused by radiation in head and neck cancer patients.
-
Proton Re-irradiation for Head and Neck Cancer Recurrence
This study tests whether proton therapy as a second round of radiation is safe and helpful for adults with head and neck cancer that has come back after prior treatment.
-
Intratumoral EDS01 plus toripalimab for recurrent or metastatic head and neck cancer
This phase 1 study tests whether directly injecting a gene‑therapy endostatin product (EDS01) into a tumor, together with the PD-1 inhibitor toripalimab, is safe and shows early signs of activity in adults with recurrent or metastatic head and neck cancer after platinum therapy.
-
Specialist nurse-led perioperative nursing care for head and neck cancer surgery
A multidisciplinary team of specialist nurses tests whether a nurse-led perioperative care plan improves recovery for people having head and neck cancer surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.